Research map: Efficacy and Safety of Once‐Weekly Semaglutide 2.0 mg as an Add‐On to Dose‐Reduced Insulin Glargine versus Dose‐Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight ( SUSTAIN OPTIMIZE )

Back to the article

Papers in this map

  1. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes · Steven P. Marso · 2016 · 6910 citations · Cited by this paper
  2. Economic Impact of Multidisciplinary Pre‐operative Diabetes Care Versus Usual Care in Adults Undergoing Elective Non‐cardiac Surgery in Australia: A Trial‐Based Analysis · 2026 · Related
  3. Pathophysiology of Type 2 Diabetes Mellitus · Unai Galicia-García · 2020 · 3336 citations · Cited by this paper
  4. Feasibility of Decentralised Response‐Guided Albuminuria Monitoring to Optimise Empagliflozin and Finerenone Therapy in Type 2 Diabetes and Chronic Kidney Disease · 2026 · Related
  5. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes · Vlado Perkovic · 2024 · 1826 citations · Cited by this paper
  6. Metformin Ameliorates Diabetes‐Associated Cognitive Dysfunction via p53/Parkin‐Mediated Mitophagy · 2026 · Related
  7. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial · Richard E. Pratley · 2018 · 790 citations · Cited by this paper
  8. Trends and Prevalence of Undiagnosed Dysglycemia Among Reproductive‐Age Women in the United States · 2026 · Related
  9. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial · CHRISTOPHER H. SORLI · 2017 · 737 citations · Cited by this paper
  10. Beyond Glycaemia: Fear of Hypoglycaemia, Cognition and Functional Mobility After Advanced Hybrid Closed‐Loop Therapy in Older Adults With Type 1 Diabetes: A Prespecified Secondary Analysis of a Randomised, Single‐Centre Study · 2026 · Related
  11. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 · Nuha A. ElSayed · 2024 · 709 citations · Cited by this paper
  12. Diagnostic Yield of Structured Cushing Syndrome Evaluation in Treatment‐Resistant Non‐Diabetic Obesity: A Retrospective Pilot Study · 2026 · Related
  13. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes · Silvio E. Inzucchi · 2015 · 698 citations · Cited by this paper
  14. Exercise Snacks Are Feasible to Perform in the Real World and Improve Physical Capacity for Adults Living With Non‐Insulin Treated Type 2 Diabetes: A Randomised Trial · 2026 · Related
  15. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study · Mark F. Peyrot · 2012 · 665 citations · Cited by this paper
  16. Real‐World Effectiveness and Safety of Finerenone in People With Type 2 Diabetes and Chronic Kidney Disease: A Spanish Multicentre Retrospective Observational Study ( MEDFINE ‐ RWD ) · 2026 · Related
  17. Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial · Andrew Ahmann · 2017 · 595 citations · Cited by this paper
  18. Sodium Butyrate Attenuates Renal Fibrosis by Regulating Glycolysis and Histone H4K12 Lactylation in Diabetic Kidney Disease · 2026 · Related
  19. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation · Ildiko Lingvay · 2021 · 587 citations · Cited by this paper
  20. Methodological and Conceptual Concerns Regarding the 24‐h Glycaemia/C‐Peptide Ratio as a Novel Insulin Sensitivity Index · 2026 · Related
  21. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial · Bo Åhrén · 2017 · 492 citations · Cited by this paper
  22. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial · Vanita R. Aroda · 2017 · 460 citations · Cited by this paper
  23. Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial · Helena W. Rodbard · 2018 · 410 citations · Cited by this paper
  24. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes · Darren K. McGuire · 2025 · 383 citations · Cited by this paper
  25. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial · Bernard Zinman · 2019 · 377 citations · Cited by this paper
  26. GLP-1 receptor agonists: an updated review of head-to-head clinical studies · Jennifer M. Trujillo · 2021 · 295 citations · Cited by this paper
  27. Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial · Juan P. Frías · 2021 · 183 citations · Cited by this paper
  28. Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges? · Philip Home · 2014 · 177 citations · Cited by this paper
  29. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial · Marc P. Bonaca · 2025 · 161 citations · Cited by this paper
  30. Effect of once‐weekly semaglutide versus thrice‐daily insulin aspart, both as add‐on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes ( SUSTAIN 11): A randomized, open‐label, multinational, phase 3b trial · Monika Kellerer · 2022 · 86 citations · Cited by this paper
  31. Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial · on behalf of the CONCLUDE Study Group · 2020 · 74 citations · Cited by this paper
  32. Glycaemic control and macrovascular and microvascular outcomes: A systematic review and meta‐analysis of trials investigating intensive glucose‐lowering strategies in people with type 2 diabetes · Setor K. Kunutsor · 2024 · 72 citations · Cited by this paper
  33. Basal Insulin Intensification in Patients with Type 2 Diabetes: A Review · Jerry Meece · 2018 · 51 citations · Cited by this paper
  34. A Randomized Clinical Trial to Evaluate the Efficacy and Safety of Co-Administration of Sitagliptin with Intensively Titrated Insulin Glargine · Chantal Mathieu · 2015 · 40 citations · Cited by this paper
  35. Relationship Between Sensor-Detected Hypoglycemia and Patient-Reported Hypoglycemia in People With Type 1 and Insulin-Treated Type 2 Diabetes: The Hypo-METRICS Study · Patrick Divilly · 2024 · 36 citations · Cited by this paper
  36. Randomized Trial of Long-Acting Insulin Glargine Titration Web Tool (LTHome) Versus Enhanced Usual Therapy of Glargine Titration (INNOVATE Trial) · HARPREET SINGH BAJAJ · 2016 · 34 citations · Cited by this paper
  37. Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme · Kristina Secnik Boye · 2023 · 19 citations · Cited by this paper
  38. Exploring the gap between sensor‐detected ( SDH ) and person‐reported hypoglycaemia ( PRH ): The voice of people living with diabetes · Monika Cigler · 2026 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)